LLY vs NVS
Lilly (Eli) and Novartis AG, both Healthcare
Lilly (Eli) is the larger company at $980B against $296B. On trailing earnings NVS is the cheaper of the two at a P/E of 21.2 against 39.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year LLY returned +55% against +20% for NVS. The RyuScore puts NVS ahead, 74 against 63 out of 100.
| Figure | LLY | NVS |
|---|---|---|
| Last close | $1179 | $144 |
| Market cap | $980B | $296B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 39.5 | 21.2 |
| Dividend yield | 0.5% | n/a |
| 1-year return | +55% | +20% |
| 5-year return | +418% | +103% |
| RyuScoresector-relative, 1–10 | 63/100 | 74/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Lilly (Eli)
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.